STUDresearch · Non-peptide
PEA
Also known as
palmitoylethanolamide · palmitoyl ethanolamide · Levagen+ · PeaPure · micronized PEA · ultra-micronized PEA · um-PEA
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral
Immune & inflammation adjacents
Systemic oral fatty-acid amide (endocannabinoid-like, PPAR-α).
What people say
PEA here means palmitoylethanolamide, an endogenous lipid sold for pain and inflammation discussion—not the stimulant phenylethylamine. Micronized, ultra-micronized and absorption-enhanced products differ; it is not a peptide.
Doses people talk about
Micronized, ultra-micronized, LipiSperse and bulk powder are not established equivalents. The legacy ~300–350 mg Levagen+ range can reflect product-label conventions; formulation mass must not automatically be treated as active PEA mass. Other therapies confound longer-term success reports.
How it may feel
Some users describe pain relief within days or about a week; others notice changes over weeks or nothing clear. Severe GI complaints and later fatigue or worsening also occur. A positive user's long-term improvement included physical therapy, so it was not PEA-only evidence.
Inspected pain report400 mg three times daily, later twice daily
One CPPS/back-pain user reported improvement after about a week; later pain-free follow-up included physical therapy, not PEA alone.
Common daily discussion300–600 mg/day
Often split twice daily in the preserved notes; no universal half-life-based frequency is established.
Higher paper/discussion band600–1200 mg/day
Includes 400 mg three-times-daily descriptions in older ultra-micronized work and community reports; higher amounts do not guarantee benefit or tolerability.
As-needed Levagen+ discussion~300–350 mg; some descriptions 600 mg/event
Pain-onset/menstrual-pain context, not the same as an ongoing daily course; exact product and active-ingredient labeling need to remain attached.
Inspected GI adverse account400 mg orally once
One user described severe GI and migraine symptoms lasting days; this is an unverified reaction report, not an incidence estimate.
Half-life & effect duration
- Half-life in the body
- Oral PEANo settled estimate
- Felt duration people report
- Relief accountsWithin days or about a week; others report uncertain benefit
- Adverse accountSevere digestive symptoms lasting days after one use
- After stoppingOne longer-term user reported difficult symptoms 3 weeks later
Cycles people discuss
Discussion often uses daily 4–8-week trials, sometimes continued without a set cycle. As-needed menstrual-pain use is a separate context. Pain returning or difficult symptoms after stopping are reports, not proof of a required taper or washout.
Timing
Food timing is debated; many reports pair oral PEA with a meal in hopes of limiting GI discomfort. That does not establish prevention of GI reactions, and the preserved twice-daily pattern is not validated by the four-hour absorption study.
Stacks
Luteolin or quercetin blends, CBD, magnesium and BPC-157 appear in pain/inflammation stacks. Co-treatments and changes in underlying pain complicate attribution to PEA alone.
Watch for
GI reactions vary: Mild rumble is reported, but some users stop for severe or persistent stomach pain, nausea or diarrhea. One 400 mg oral report described symptoms lasting a week and sought medical care; other commenters described recurrence after restarting. These are unverified anecdotes, not incidence estimates.
Tap a line for the full notes and source context.
Timing context & sources
Half-life in the body
The reviewed LipiSperse comparison does not establish a terminal PEA half-life.
It measured plasma uptake over 4 hours and reported greater baseline-adjusted AUC for LipiSperse. Concentrations had not returned to baseline when sampling ended. Exposure, not elimination or duration of pain relief, was the primary endpoint.
The abstract and table describe differing peak timings, so no single Tmax is imposed. This conclusion is limited to the inspected products/study; no universal half-life claim is made for newer hybrid-hydrogel formulations. Product-sponsored evidence is not a validated BID schedule.
- Briskey, Mallard & Rao — Increased Absorption of Palmitoylethanolamide Using LipiSperse (opens in a new tab)2020;5(2):3, DOI 10.36648/nutraceuticals.5.2.3. PDF pp 1–4: 28 healthy adults, parallel groups of 14, single 300 mg PEA dose; Table 1 baseline-adjusted AUC over 0–4 hours; Discussion says sampling ended before return to baseline. Funding on p 5.Full original article read via PDF mirror after publisher web timeouts; direct publisher HTML later returned HTTP 200. Not a terminal half-life study. Abstract 45-minute peak and Table 1 mean peak timing of 105/125 minutes are not silently treated as one Tmax. Product/sponsor support from Pharmako/Gencor; no twofold clinical-benefit inference.
Felt duration people report
Reports include benefit within days or about a week, weeks-long trials, uncertain response and adverse symptoms persisting after stopping; no universal felt-duration range is established.
A 400 mg TID then BID report described early relief and later physical therapy. Another 400 mg single-use account described severe GI symptoms lasting days; an 800 mg powder user reported no GI effects but uncertain benefit with medication confounding. A 600 mg/day five-month user described difficult symptoms three weeks after stopping.
Different users and disorders are not pooled into a dose-response curve. Withdrawal-like language is the person's description, not an established syndrome. Supplement status and tolerability in a short trial do not erase adverse community reports.
- Natural Painkiller: PEA — early relief and later physical-therapy follow-up (opens in a new tab)Ordinary-Bridge8182: pain manageable after about 1 week, 400 mg TID then BID; same author's later reply adds PT and intermittent 1–2 pills/day for around a week. Another participant disputes meaningful pain relief (opened lines 48–85, 126–132).Anonymous CPPS/back-pain account with later physical therapy and no controlled timing. The post's opioid-replacement pitch is not adopted. Later pills are not converted to mass from another user's assumptions.
- Palmitoylethanolamide — severe stomach pain and follow-up reports (opens in a new tab)JohnTCarter OP: 400 mg oral with lunch, severe GI/migraine symptoms lasting days, still in pain at 1 week and medical follow-up. WantToBeHealthy246 describes stop/restart recurrence. Yoga31415 reports 800 mg powder with no GI symptoms but uncertain benefit, later amitriptyline confounding (opened lines 19–24, 53–108, 218–252).Self-reports do not establish causality or incidence. Positive tolerability and severe reactions both retained; no advice to rechallenge adopted. Different commenters are not merged into one follow-up history.
- Micronized PEA — initial benefit followed by symptoms and difficult discontinuation (opens in a new tab)IntroductionOdd411 OP: 600 mg/day for about 5 months, initial sleep/joint/nerve/sun-tolerance benefit, later fatigue/headache/balance/sleep/constipation/memory complaints, off for 3 weeks with withdrawal-like worsening (opened lines 18–22).A single unverified, condition-confounded report with no objective withdrawal diagnosis or subsequent recovery demonstrated. It prevents a categorical no-rebound claim; it does not establish a PEA withdrawal syndrome.
What people say
- Chronic pain logs: r/ChronicPain and supplement threads describe a slow drop in background ache over 2–8 weeks, not a day-one mute. forum
- Mast-cell / “histamine” lore: People add PEA + luteolin (Palmitoylethanolamide + flavonoid) for flushing and itch. Attribution is messy. forum
- Sleep as a side-effect of less pain: Not a melatonin replacement. forum
- Does nothing for a subset — the other half of every PEA thread. forum
- 300–600 mg band: Reviews keep circling 300 / 600 / 1200 mg as the doses that actually show up in human work. trial
- Levagen+ 300–600 mg: Vendor-funded studies (training soreness, menstrual pain as-needed, 6–12 week daily) are what 2025–26 ads paste. trial
Doses people talk about
- Higher paper band: 600–1200 mg/day (sometimes 400 mg TID in older um-PEA work). The inspected community thread also includes 400 mg three times daily, later twice daily, with early pain relief; later physical therapy confounded the same author's longer-term outcome. trialanecdote
- Micronized vs um-PEA vs Levagen+: Compare product to product; 300 mg LipiSperse ≠ 300 mg cheap powder in those ads. forum
- Give it weeks is the copied instruction. forum
- Common daily: 300–600 mg, often split BID. trial
- Levagen+ as-needed: ~300–350 mg at pain onset; some protocols 600 mg/event. trial
- Framing: Supplement milligrams — not a prescription. forum
How it may feel
- Days 1–7: Most feel nothing. A few get GI rumble. Not a benzo. forum
- Weeks 2–4: First “maybe the baseline is quieter” comments. People who wanted instant relief have already quit. In an inspected CPPS/back-pain thread, a user reported improvement after about 1 week at 400 mg three times daily, later twice daily. The same author's later pain-free update also included physical therapy; it was not PEA-only proof. forumanecdote
- After stopping: Some reports describe underlying pain returning rather than an opioid-like rebound. That is not universal: one micronized-PEA reporter described initial benefit at 600 mg/day for about 5 months, later adverse symptoms, and a withdrawal-like worsening persisting about 3 weeks after stopping. The mechanism and causality were not established. anecdote
- Weeks 6–8: The window Levagen+/pain papers like. trial
- As-needed menstrual logs: 300–600 mg at onset in those studies — a different pattern than daily chronic-pain caps. trial
Cycles people discuss
- Daily for chronic pain tries: 4–8 weeks before calling it. forum
- Open-ended if they think it helps; no receptor-downregulation ritual. forum
- Stack-stripping: People who added PEA + luteolin + quercetin on day one cannot tell what worked. forum
- As-needed only in menstrual/acute vendor studies — not the nerve-pain pattern. trial
Timing
- With or without food is argued; many just swallow with a meal to skip GI. forum
- Felt onset is mixed: The common PPAR-α/lipid-signaling story anticipates gradual relief rather than an ibuprofen-like kick. Some users nevertheless report benefit within days or about a week, while others need weeks, feel nothing, or have adverse effects; a universal onset or per-dose relief duration is not established. forum
- Formulation matters: Ultra-micronized, standard, LipiSperse and other delivery systems concern absorption and potentially the concentration-time profile. A result for one product cannot establish the half-life or effective amount of another. forum
- Plasma exposure is not the pain clock: The older “hours, not a 17-hour DORA” comparison is not a measured PEA half-life. Briskey's 300 mg oral formulation study sampled only 4 hours and measured AUC/peaks, with levels not back to baseline at the endpoint. That study does not establish elimination half-life or validate BID dosing. trial
More on what it is
- Why people talk about it: Pain and mast-cell boards, plus 2024–26 Levagen+ ads. Peptide-adjacent only because biohack stacks put it next to BPC for “inflammation.” forum
- Not phenylethylamine. Search “PEA nootropic” and you get two molecules. This card is the pain lipid. Phenylethylamine is the stimulant-ish cousin. forum
- What it is: Palmitoylethanolamide — a lipid your body already makes. Sold as 300–600 mg micronized or ultra-micronized caps (Levagen+, PeaPure). Not a peptide. trial
- How it works (plain): Hits PPAR-α and turns down inflammatory chatter; related to the endocannabinoid neighborhood without being THC/CBD. Slow, not a knockout painkiller. trial
- Micronized vs regular: Smaller particle = the absorption pitch. Levagen+ (LipiSperse) claims roughly 2× plasma vs standard PEA in the vendor study people quote. The inspected 2020 comparison used 300 mg PEA per group and reported about 1.7-fold baseline-adjusted 0–4-hour AUC, not a twofold half-life or guaranteed twofold pain relief. trial
- Evidence posture: Pain/inflammation papers at 300–1200 mg. Not an opioid, not a steroid. trial
Stacks
- Solo 300–600 mg first: The only way to know if the lipid is doing anything. forum
- + Luteolin / quercetin: Mast-cell “PEA + flavonoid” posts. forum
- + CBD / mag: Same pain-sleep drawer. forum
- + BPC-157: Peptide-room inflammation stack — two different evidence piles. forum
Storage notes
- Capsules. No BAC water. Cool, dry. forum
- Keep PEA (lipid) vs PEA (phenylethylamine) bottles labeled. forum
Watch for
- Slow or nothing: A common disappointment, but not the only experience; adverse reactions also appear in community reports and cannot be dismissed from supplement status alone. forum
- GI reactions vary: Mild rumble is reported, but some users stop for severe or persistent stomach pain, nausea or diarrhea. One 400 mg oral report described symptoms lasting a week and sought medical care; other commenters described recurrence after restarting. These are unverified anecdotes, not incidence estimates. forum
- Wrong PEA: Phenylethylamine stimulant-ish vs this lipid. forum
- Not an opioid substitute in a crisis. forum
- Identity: Micronized vs bulk powder is the product. forum
- Vendor-funded Levagen+ papers are real and also marketing. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.